Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 4/20 | 0.41 |
| ▸ | MEP1A | Q16819 | 2/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27447668 | 0.85 | CYP4F2 (0.44) | ALDH1A1TSHRFOLH1MEP1BMEP1A | |
| SCHEMBL2062793 | 0.83 | CES2 (0.48) | ALDH1A1TSHRCES2CES1FOLH1 | |
| SCHEMBL4950108 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TSHRFOLH1PTPN1LOXL2 | |
| SCHEMBL29572523 | 0.83 | ATM (0.52) | ALDH1A1TSHRCES2CES1FOLH1 | |
| SCHEMBL185962 | 0.83 | ATM (0.52) | ALDH1A1TSHRCES2CES1FOLH1 | |
| SCHEMBL39676 | 0.82 | TSHR (0.47) | ALDH1A1TSHRFOLH1LOXL2CYP4F2 | |
| SCHEMBL16240333 | 0.82 | PRSS1 (0.55) | ALDH1A1TSHRFOLH1LOXL2CYP4F2 | |
| SCHEMBL40393 | 0.82 | FOLH1 (0.66) | CES2CES1FOLH1MEP1BMEP1A | |
| SCHEMBL29472003 | 0.82 | TSHR (0.47) | ALDH1A1TSHRFOLH1LOXL2CYP4F2 | |
| SCHEMBL29964040 | 0.82 | FOLH1 (0.66) | CES2CES1FOLH1MEP1BMEP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | CELLGENTEK CO., LTD. (KR) | 2023-05-18 | — | — | US | disclosed |
| EP-4019495-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | Cellgentek Co., Ltd (KR) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021034087-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | 주식회사 셀젠텍 | 2021-02-25 | — | — | WO | disclosed |
| CN-106132939-B | Process for producing tetrazolinone compound | 住友化学株式会社 | 2018-11-13 | — | — | CN | disclosed |
| CN-108409678-A | The manufacturing method of Terazololine-one compound | 住友化学株式会社 | 2018-08-17 | — | — | CN | disclosed |
| CN-105518014-B | C-aryl glucoside derivative, preparation method and application thereof in medicine | 上海研健新药研发有限公司 | 2018-03-23 | — | — | CN | disclosed |
| EP-2590656-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| CN-107311992-A | C aryl glucosides derivative, its preparation method and its in application pharmaceutically | 上海研健新药研发有限公司 | 2017-11-03 | — | — | CN | disclosed |
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2017-02-09 | — | — | US | disclosed |
| EP-2590510-B1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX INC (US) | 2016-09-28 | — | — | EP | disclosed |
| US-5234918-A | For cardiovascular, respiratory, carcinogenic and inflammatory disorders | AMERICAN CYANAMID COMPANY (US) | 1993-08-10 | — | — | US | disclosed |
| US-5231182-A | Platelet activating factor inhibitor | AMERICAN CYANAMID COMPANY (US) | 1993-07-27 | — | — | US | disclosed |
| US-5225425-A | Respiratory system disorders | AMERICAN CYANAMID COMPANY (US) | 1993-07-06 | — | — | US | disclosed |
| US-5215975-A | Certain hydroxy-phosphinyl-oxy-phenyl methyl-thiazolium hydroxide inner salts as PAF antagonists | AMERICAN CYANAMID COMPANY (US) | 1993-06-01 | — | — | US | disclosed |
| US-5128351-A | BIS-ARYL AMIDE AND UREA ANTAGONISTS OF PLATELET ACTIVATING FACTOR | AMERICAN CYANAMID COMPANY (US) | 1992-07-07 | — | — | US | disclosed |
| US-5077409-A | Reducing hydroxy bis-aryl amide, acylating, hydrolyzing, sulfonating, halogenating, alkylating with nitrogen heterocycle | AMERICAN CYANAMID COMPANY (US) | 1991-12-31 | — | — | US | disclosed |
| EP-0458037-A1 | Bis-aryl amide and urea antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1991-11-27 | — | — | EP | disclosed |
| EP-0336142-A2 | Novel antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1989-10-11 | — | — | EP | disclosed |
| US-4066435-A | BENZYL TRIALKYL PHOSPHONIUM HALIDE | MONSANTO COMPANY (US) | 1978-01-03 | — | — | US | disclosed |
| US-4053501-A | PLANT GROWTH REGULATORS | MONSANTO COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037010-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A2, SLC34A1, SLC10A2 | ALDH1A1 2892/4885TSHR 3105/4885CES2 879/4885 |
| US-20230150924-A1 | NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND | KNTC1, MED1, LEF1 | ALDH1A1 1404/4885TSHR 4826/4885CES2 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.